

Westminster Health Forum policy conference

Next steps for highly specialised medicines, regulation and treatment - Evaluation, evidence, innovation, orphan drugs, genomics, and patient access and involvement

Timing: Morning, Thursday 19th May 2022

Taking Place Online



WESTMINSTER
HEALTH FORUM

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**
Angela McFarlane, Vice President, Strategic Planning Northern Europe, IQVIA
- 9.05 **The future outlook for highly specialised technology evaluation**
Sheela Upadhyaya, Rare Diseases and Rapid-C19 Strategic Advisor, Centre for Health Technology Evaluation, NICE
Questions and comments from the floor
- 9.30 Break
- 9.35 **New approaches to evaluation - opportunities, challenges and implementation**
- 'Making the most of the Innovative Medicines Fund and new NICE methods and processes'*
Dr Paul Catchpole, Director, Value and Access Policy, ABPI
- 'New approaches in addressing challenges in orphan drug development'*
Dr Mark MacGregor, Chairman, Scottish Medicines Consortium
- 'Ensuring a sustainable system for rare diseases'*
Sean Richardson, Vice President and General Manager, UK and Ireland, Alexion, AstraZeneca Rare Disease
- 'Improving patient access to innovation and utilising their experience'*
Toni Mathieson, Chief Executive, Niemann-Pick UK and Chair, LSD Collaborative
- 'Achieving value for money in healthcare assessments'*
Martina Garau, Director, Office of Health Economics
- 10.25 Questions and comments from the floor
- 10.50 **The Innovative Medicines Fund and improving patient access to innovation - scope, priorities and looking forward**
Brad Groves, Associate Director, Managed Access, NICE
Questions and comments from the floor
- 11.10 **Chair's closing remarks**
Angela McFarlane, Vice President, Strategic Planning Northern Europe, IQVIA
- 11.15 Break
- 11.25 **Chair's opening remarks**
Dr Neil Ebenezer, Medical Technology and Genomics Specialist, Department for International Trade
- 11.30 **Taking forward the opportunities presented by genomics**
Dr Richard Scott, Chief Medical Officer, Genomics England
Questions and comments from the floor
- 11.50 **Research and development in highly specialised treatments - priorities, investment, opportunities for collaboration, and latest thinking on delivering innovative interventions earlier in the course of disease**
Angela McFarlane, Vice President, Strategic Planning Northern Europe, IQVIA
Richard Hebdon, Director, Health & Life Sciences, Innovate UK
Catriona Crombie, Associate Director, Technology Transfer and Philanthropic Fund, LifeArc
- 12.05 Questions and comments from the floor
- 12.25 Break
- 12.30 **The way forward for regulation - utilising data, responding to innovation, and the UK's international role**
Dr Marc Bailey, Chief Science and Innovation Officer, Medicines and Healthcare products Regulatory Agency (MHRA)
Questions and comments from the floor
- 12.55 **Chair's and Westminster Health Forum closing remarks**
Dr Neil Ebenezer, Medical Technology and Genomics Specialist, Department for International Trade
Jessica Lear, Producer, Westminster Health Forum

Conference supported by Alexion, AstraZeneca Rare Disease

